Mersana Therapeutics is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates (ADCs) for cancer patients. Co.'s platforms including Dolaflexin and Dolasynthen, deliver its auristatin DolaLock payload, as well as Immunosynthen, which delivers its stimulator of interferon genes (STING) agonist ImmunoLock payload. Co.'s product candidates include: upifitamab rilsodotin (UpRi), which is a Dolaflexin ADC targeting NaPi2b, an antigen expressed in ovarian cancer and other cancers; and XMT-1592, which is a Dolasynthen ADC targeting NaPi2b-expressing tumor cells. The MRSN average annual return since 2017 is shown above.
The Average Annual Return on the MRSN average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MRSN average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MRSN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|